AbbVie (NYSE:ABBV) Earns Outperform Rating from Royal Bank Of Canada

AbbVie (NYSE:ABBV)‘s stock had its “outperform” rating reissued by stock analysts at Royal Bank Of Canada in a report issued on Tuesday, Benzinga reports. They presently have a $280.00 target price on the stock. Royal Bank Of Canada’s price target would indicate a potential upside of 1.88% from the company’s previous close.

A number of other brokerages have also weighed in on ABBV. BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Scotiabank upped their target price on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Barclays raised their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $225.00 price target (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. Finally, HSBC increased their price target on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $277.18.

AbbVie Trading Down 2.2%

AbbVie stock traded down $6.30 during trading hours on Tuesday, hitting $274.82. 6,388,665 shares of the stock traded hands, compared to its average volume of 6,414,528. The firm’s 50-day moving average price is $259.79 and its two-hundred day moving average price is $237.39. AbbVie has a one year low of $190.75 and a one year high of $283.43. The company has a market cap of $485.55 billion, a PE ratio of 77.63, a PEG ratio of 1.26 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the firm posted $2.97 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts expect that AbbVie will post 13.94 earnings per share for the current fiscal year.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp raised its holdings in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. Corient Private Wealth LP bought a new stake in AbbVie during the 2nd quarter worth about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares during the last quarter. Legal & General Group Plc bought a new stake in AbbVie during the 2nd quarter worth about $2,905,952,000. Finally, Deutsche Bank AG increased its stake in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after acquiring an additional 1,241,587 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Fresh clinical and regulatory developments are strengthening AbbVie’s long-term growth story. Phase 3 data for SKYRIZI and RINVOQ in Crohn’s disease, Breakthrough Therapy Designations for temab-A in colorectal and lung cancer, and early obesity-treatment data could expand the company’s pipeline beyond its existing immunology franchise. AbbVie Could Be 44% Below Fair Value On Fresh Pipeline Wins
• Positive Sentiment: Long-term SKYRIZI and RINVOQ data presented at ACG 2026 support the view that the two drugs can continue offsetting the loss of Humira revenue. Their expected contribution is a key focus ahead of AbbVie’s next earnings report. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings
• Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and assigned a $280 price target, signaling continued confidence in AbbVie’s earnings and pipeline execution. RBC Reaffirms AbbVie Outperform Rating
• Neutral Sentiment: Analysts continue comparing AbbVie with Eli Lilly, highlighting AbbVie’s diversified immunology growth while noting Lilly’s stronger exposure to the rapidly expanding cardiometabolic market. AbbVie vs. Eli Lilly
• Negative Sentiment: Despite encouraging developments, AbbVie trades at a high earnings multiple after a substantial rally, while RBC’s $280 target implies only limited upside. Ongoing Humira erosion, rising immunology competition, and uncertainty around pipeline commercialization may be prompting profit-taking and valuation concerns.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.